Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

por Beloueche-Babari, M, Jamin, Y, Arunan, V, Walker-Samuel, S, Revill, M, Smith, P D, Halliday, J, Waterton, J C, Barjat, H, Workman, P, Leach, M O, Robinson, S P
Publicado 2013